HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons

Bihl, Florian ; Martinetti, Gladys ; Wandeler, Gilles ; Weber, Rainer ; Ledergeber, Bruno ; Calmy, Alexandra ; Battegay, Manuel ; Cavassini, Matthias ; Vernazza, Pietro ; Caminada, Anna-Paola ; Rickenbach, Martin ; Bernasconi, Enos

Abstract: BACKGROUND: Hepatitis B virus (HBV) genotypes can influence treatment outcome in HBV-monoinfected and human immunodeficiency virus (HIV)/HBV-coinfected patients. Tenofovir disoproxil fumarate (TDF) plays a pivotal role in antiretroviral therapy (ART) of HIV/HBV-coinfected patients. The influence of HBV genotypes on the response to antiviral drugs, particularly TDF, is poorly understood. METHODS: HIV/HBV-co-infected participants with detectable HBV DNA prior to TDF therapy were selected from the Swiss HIV Cohort Study. HBV genotypes were identified and resistance testing was performed prior to antiviral therapy, and in patients with delayed treatment response (>6 months). The efficacy of TDF to suppress HBV (HBV DNA <20 IU/mL) and the influence of HBV genotypes were determined. RESULTS: 143 HIV/HBV-coinfected participants with detectable HBV DNA were identified. The predominant HBV genotypes were A (82 patients, 57 %); and D (35 patients, 24 %); 20 patients (14 %) were infected with multiple genotypes (3 % A + D and 11 % A + G); and genotypes B, C and E were each present in two patients (1 %). TDF completely suppressed HBV DNA in 131 patients (92 %) within 6 months; and in 12 patients (8 %), HBV DNA suppression was delayed. No HBV resistance mutations to TDF were found in patients with delayed response, but all were infected with HBV genotype A (among these, 5 patients with genotype A + G), and all had previously been exposed to lamivudine. CONCLUSION: In HIV/HBV-coinfected patients, infection with multiple HBV genotypes was more frequent than previously reported. The large majority of patients had an undetectable HBV viral load at six months of TDF-containing ART. In patients without viral suppression, no TDF-related resistance mutations were found. The role of specific genotypes and prior lamivudine treatment in the delayed response to TDF warrant further investigation.

DOI: https://doi.org/10.1186/s12876-015-0308-0
Bihl, Florian; Martinetti, Gladys; Wandeler, Gilles; Weber, Rainer; Ledergerber, Bruno; Calmy, Alexandra; Battegay, Manuel; Cavassini, Matthias; Vernazza, Pietro; Caminada, Anna-Paola; Rickenbach, Martin; Bernasconi, Enos (2015). HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons. BMC Gastroenterology, 15:79. DOI: https://doi.org/10.1186/s12876-015-0308-0
HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons

Florian Bihl1*, Gladys Martinetti2, Gilles Wandeler3, Rainer Weber4, Bruno Ledergerber4, Alexandra Calmy5, Manuel Battegay6, Matthias Cavassini7, Pietro Vernazza8, Anna-Paola Caminada9, Martin Rickenbach9, Enos Bernasconi10 and Swiss HIV Cohort Study

Abstract

Background: Hepatitis B virus (HBV) genotypes can influence treatment outcome in HBV-monoinfected and human immunodeficiency virus (HIV)/HBV-coinfected patients. Tenofovir disoproxil fumarate (TDF) plays a pivotal role in antiretroviral therapy (ART) of HIV/HBV-coinfected patients. The influence of HBV genotypes on the response to antiviral drugs, particularly TDF, is poorly understood.

Methods: HIV/HBV-co-infected participants with detectable HBV DNA prior to TDF therapy were selected from the Swiss HIV Cohort Study. HBV genotypes were identified and resistance testing was performed prior to antiviral therapy, and in patients with delayed treatment response (>6 months). The efficacy of TDF to suppress HBV (HBV DNA <20 IU/mL) and the influence of HBV genotypes were determined.

Results: 143 HIV/HBV-coinfected participants with detectable HBV DNA were identified. The predominant HBV genotypes were A (82 patients, 57%); and D (35 patients, 24%); 20 patients (14%) were infected with multiple genotypes (3% A + D and 11% A + G); and genotypes B, C and E were each present in two patients (1%). TDF completely suppressed HBV DNA in 131 patients (92%) within 6 months; and in 12 patients (8%), HBV DNA suppression was delayed. No HBV resistance mutations to TDF were found in patients with delayed response, but all were infected with HBV genotype A (among these, 5 patients with genotype A + G), and all had previously been exposed to lamivudine.

Conclusion: In HIV/HBV-coinfected patients, infection with multiple HBV genotypes was more frequent than previously reported. The large majority of patients had an undetectable HBV viral load at six months of TDF-containing ART. In patients without viral suppression, no TDF-related resistance mutations were found. The role of specific genotypes and prior lamivudine treatment in the delayed response to TDF warrant further investigation.

Background

Hepatitis B virus (HBV) infection is one of the most frequent causes of end-stage liver disease. Due to shared modes of transmission, coinfection with human immunodeficiency virus (HIV) and HBV is frequent, and represents a global public health challenge [1]. HIV/HBV-coinfected patients, particularly those with low CD4 cell counts, are at increased risk for liver-related mortality [2–5].

Progression of HBV-related liver disease is influenced by viral factors, such as viral load, genotype, the presence of hepatitis B e antigen (HBeAg), and the appearance of escape mutations [6–11].

The natural history of HBV infection in HIV-coinfected individuals is modified by [5, 12]. nucleos(t)ide analogues (NUCs), such as lamivudine (LAM), tenofovir disoproxil fumarate (TDF), and emtricitabine (FTC), if used as components of antiretroviral therapy (ART). Moreover, recent studies showed that these HBV-specific agents not only prevent liver deterioration, but can also lead to seroconversion of HBeAg and even hepatitis B surface antigen.
(HBsAg) [12]. TDF, alone or combined with FTC, is a recommended component of an ART regimen for HIV/HBV-coinfected patients because of its potent antiviral activity against HIV and HBV and its excellent resistance profile [13–15]. Indeed, no convincing evidence of HBV resistance mutations against TDF has been described to date [16]. Nevertheless, TDF and FTC fail to completely suppress HBV viral load in some HIV/HBV-coinfected patients [17, 18]. A recent long-term analysis of the effects of TDF on HIV/HBV over 55 months showed a lack of virological response in 10 % of patients, who subsequently required entecavir rescue therapy [18].

HBV is classified into eight genotypes, designated A to H, based on a sequence polymorphism of more than 8 % [19]. In HBV mono-infection, viral genotypes have diverse geographical distribution, different routes of infection, and are associated with distinct disease progression and treatment responses [20–22]. HBV genotype distribution in HIV/HBV coinfection appears to be influenced by the route of infection, and to interfere with the natural history of liver disease [6, 9–11, 23]. Importantly, some HBV genotypes may hamper the efficacy of NUCs in HBV-mono-infected patients [21]. We aimed to evaluate the impact of HBV genotype on the efficacy of TDF in the treatment of HIV/HBV-coinfected patients.

Methods
Patient population
All patients were adults and were enrolled in the Swiss HIV Cohort Study (SHCS), which is a large prospective cohort study with continuous enrollment of HIV-infected individuals and followed in HIV outpatient clinics at 7 Swiss hospitals (Basel, Bern, Geneva, Lausanne, Lugano, St. Gallen, Zurich) [24]. The institutional review board of the Hospital where patients were recruited (Zurich, Basel, Bern, Geneva, Lausanne, Lugano and St. Gallen) approved the study and all subjects signed an informed consent before enrollment in the study. Patients were followed every six months with a study visit during which laboratory parameters were measured and plasma samples taken. All data, including laboratory results, were transmitted to a data center and plasma samples were stored at −80 °C. For this study, the following demographic and clinical characteristics were extracted: HBsAg, anti-HBc, HBeAg, anti-HBe, anti-HDV, anti-HCV and HCV RNA viremia, sex, age, date of first HIV test, route of transmission (risk group), region of origin, ethnicity, HIV viremia, ART (on treatment, off treatment, or treatment naïve), start of first HIV treatment, CD4 cell counts, alanine transaminase (ALT), aspartate transaminase (AST), international normalized ratio (INR), total bilirubin, serum albumin and creatinine.

HBV analyses
Stored plasma samples taken before exposure to TDF were selected and analyzed for HBV DNA. In patients with detectable HBV DNA, it was amplified, HBV genotypes identified, and resistance testing performed. DNA was extracted using a commercially available extraction kit (QIAamp DNA Mini Kit). Plasma samples of patients were screened with an HBV SYBR real-time polymerase chain reaction (PCR) analyser (realtime quantitative Cobas AmpliPrep/Cobas Taqman HBV Test v1.0, Roche SA, Switzerland) with a lower limit of detection of 20 IU/ml as described previously [25]. This preliminary PCR allowed us to screen for those samples with enough DNA to be further analyzed.

For genotyping analysis, DNA was amplified by using primers specific for the preS1/preS2 region of HBV (nucleotides 3025 to 80 from the theoretical EcoR1 site of the 3,221-nucleotide HBV sequences) as described [26]. The expected amplification product of 277 bp was used for HBV genotyping by means of a direct sequencing analysis using an automated sequencer (ABI Prism 3100, Applied Biosystems, USA). Sequence data for the amplified region of HBV-DNA were aligned with preS1/preS2 sequences from among 80 GeneBank sequences of known genotype representing eight HBV genotypes. Alignment of the sequences was performed with ClustalX software (version 1.81). Phylogenetic trees were constructed by the UPGMA method with MEGA (version 4.0) [27]. If phylogenetic analysis did not clearly determine the genotype, mostly due to insufficient quality of the generating sequences, a commercial line probe assay (InnoLiPa HBV genotype v2.0 assay, Innogenetics, Ghent, Belgium), which determines the HBV genotype using specific sequences of the S region of the HBV genome, was used to validate the genotype.

For monitoring of drug resistance amplification of DNA with a nested PCR approach was used. DNA of the HBpol region was amplified with primers described by Stuyver and coworkers [28], and sequenced as described above. Data were analyzed using HepSEQ database, a web-accessible, quality-based, molecular, clinical and epidemiological database for hepatitis B. While analyzing the nested amplification product of 341 bp long, the HepSEQ database assigns genotype and annotates known resistance mutations.

If genotype analysis using both methods did not match, generating genotype A on the preS region and genotype G on the HBpol region, involvement of mixed genotype infections was supposed. Primers described by Osiowy et al. on the preS region contain mismatching nucleotides for genotype G at the 3′ end and therefore in mixed infections, amplification of genotype G was poorer comparing to genotype A [29]. Based on HBV sequences on GeneBank, a new forward primer was
designed to selectively amplify genotype G on the preS region (100 % matching) to be used in addition of preS1R as reverse primer. The sequence of this sense primer preS1GF was 5′-AGGTAGGAGTTGGAGCTATGG-3′. Amplification conditions remained the same as described and both genotypes could be amplified.

Three patients showing mixed infections (genotype A and D) with preS and HBpol region were confirmed to be mixed infection with commercial Inno-Lipa HBV genotyping.

Efficacy of TDF on HBV suppression
The efficacy of TDF to suppress HBV was defined as HBV DNA below the limit of detection (<20 IU/mL) as assessed with patients belonging to the Cohort on the routine basis, within six months from start of treatment. In patients where complete HBV suppression was not achieved with TDF, HBV subtype and treatment history were determined and repeated post-TDF plasma samples were analyzed for HBV viremia and genotypic resistance.

Statistical methods
Fisher’s exact test and non-parametric Mann–Whitney U-test were used for comparison of categorical and continuous variables, respectively. Statistics were computed using Stata 11/SE (StataCorp LP, College Station, Texas, 77845 USA). All tests were two-tailed with significance level at 0.05.

Results
Analysis population and baseline characteristics
In 2008, a total of 15,139 participants were included in the SHCS and, of these, 7,038 were on follow-up. Of these, 3,492 (49.6 %) had anti-HBc positive status, and 388 had positive HBsAg serology (11 %). Of the HBsAg-positive participants, 271 had been exposed to TDF (Fig. 1). HBV DNA was detectable in 143 and undetectable in 128 persons before the initiation of TDF.

Baseline data for the 271 TDF-treated patients included in this analysis are summarized in Table 1. Patients with or without detectable HBV DNA were comparable; no differences were found for baseline demographic parameters (data not shown). Also, baseline clinical characteristics were similar between the two groups with the exception of median serum ALT levels of patients with detectable HBV DNA (slightly above normal at 47 IU/L (range 11–1020 IU/L, normal < 45 IU/L)), with no statistical differences observed between the genotypes.

HBV genotype distribution
HBV DNA was extracted and the HBV genotype determined in all 143 patients with detectable HBV DNA. Genotype was determined by phylogenetic analyses in 120 patients and by a commercial line probe assay in 23 patients. The predominant genotypes were A (82 patients, 57 %) and D (35 patients, 24 %). 20 patients (14 %) were infected with multiple genotypes (4 patients (3 %) A + D; 16 patients (11 %) A + G). Genotypes B, C and E were each present in two individuals (1 %) (Table 2). The genotype distribution varied among the transmission risk groups: Genotype A was most prevalent in men who have sex with men (MSM; 66 patients, 46 %), followed by the heterosexual transmission group (22 patients, 15 %), whereas genotype D was predominant in intravenous drug users (IDU; 25 patients, 17 %).

![Fig. 1 Analysis population](image-url)
The majority of multiple HBV genotype infections was found in MSM (13/20, 65 %) and was less common in heterosexual persons (4/20, 20 %), or in IDUs (2/20, 10 %).

In one patient, a genotype D infection with a high HBV DNA level (200,000 IU/mL) was detected in 2003 before he received drugs active against HBV. Later he was treated with pegylated interferon for 6 months and, one year later, received a combination of LAM and TDF for 16 months and then stopped for a structured treatment interruption (STI) of the ART. When the STI started, HBV DNA was suppressed and telbivudine treatment was initiated; at this point the HBV genotype was A + G. Six months later, HBV DNA became slightly positive (511 IU/mL) and the detected genotype was A + G + D. No HBV resistance mutations were detected in this patient.

**HDV and HCV co-infection**

HDV serology was tested in 38 patients and it was positive in 13 patients (34 %), HBV genotype was determined in 9 out of 13 HDV positive patients, 6 were genotype A and 3 genotype D. Furthermore HCV serology was known in 141 individuals; anti-HCV was identified in 31

---

**Table 1** Baseline demographic and clinical characteristics of TDF-treated HIV/HBV co-infected patients

|                          | Detectable HBV DNA | Undetectable HBV DNA |
|--------------------------|--------------------|----------------------|
| **Origin:**              |                    |                      |
| Caucasian                | 121 (84 %)         | 88 (68 %)            |
| African                  | 16 (11 %)          | 36 (28 %)            |
| Asian                    | 10 (4 %)           | 4 (3 %)              |
| **Age in years (median)**| (range) 41 (23–73) | (range) 40 (21–75)   |
| **Sex**                  | M:F                |                      |
| (range)                  | 122 (85 %):21 (15 %) | 101 (79 %):27 (21 %) |
| **CD4 count (median)**   | (range) 295 (6–1143) | 326 (21–1512)       |
| **HIV viremia (median)** | (range) 2.84 (0–6.08) | 1.74 (0–6.01)       |
| **HIV treatment**        |                    |                      |
| on HAART                 | 82 (57 %)          | 84 (66 %)            |
| treatment naïve          | 31 (22 %)          | 15 (12 %)            |
| off HAART                | 30 (21 %)          | 29 (23 %)            |
| **Hepatitis delta infection** |                  |                      |
| positive                 | 9                  | 4                    |
| negative                 | 17                 | 8                    |
| missing data             | 117                | 116                  |
| **HCV coinfection**      |                    |                      |
| positive                 | 31                 | 37                   |
| negative                 | 110                | 87                   |
| missing data             | 2                  | 4                    |
| **ALT (median)**         | (range) 47 (11–1020) | 32 (7–284)          |
| **AST (median)**         | (range) 35 (19–375) | 33 (14–135)          |
| **INR (median)**         | (range) 1 (0.9–2.6) | 1 (0.9–1.2)          |
| **Total Bilirubin (median)** | (range) 9 (4–243) | 9 (2–30)             |
|                         | (range) 39 (20–49) | 39 (32–52)           |
|                         | (range) 77 (37–214) | 76 (41–150)          |

**Table 2** Distribution of HBV genotypes of TDF-treated HIV/HBV co-infected patients

| Genotype | Heterosexual | IVDU | MSM | Other | Unknown |
|----------|--------------|------|-----|-------|---------|
| A        | 22           | 3    | 53  | 2     | 2       |
| A + D    | 1            | 1    | 2   | 0     | 0       |
| A + G    | 3            | 1    | 11  | 0     | 1       |
| B        | 1            | 0    | 1   | 0     | 0       |
| C        | 2            | 0    | 0   | 0     | 0       |
| D        | 5            | 25   | 4   | 0     | 1       |
| E        | 2            | 0    | 0   | 0     | 0       |
| Total n  | 143          | 36 (25 %) | 30 (21 %) | 71 (50 %) | 2 (1 %) | 4 (3 %) |

(p = 0.02) (Table 2). The majority of multiple HBV genotype infections was found in MSM (13/20, 65 %) and was less common in heterosexual persons (4/20, 20 %), or in IDUs (2/20, 10 %).

In one patient, a genotype D infection with a high HBV DNA level (200,000 IU/mL) was detected in 2003 before he received drugs active against HBV. Later he was treated with pegylated interferon for 6 months and, one year later, received a combination of LAM and TDF for 16 months and then stopped for a structured treatment interruption (STI) of the ART. When the STI started, HBV DNA was suppressed and telbivudine treatment was initiated; at this point the HBV genotype was A + G. Six months later, HBV DNA became slightly positive (511 IU/mL) and the detected genotype was A + G + D. No HBV resistance mutations were detected in this patient.

**HDV and HCV co-infection**

HDV serology was tested in 38 patients and it was positive in 13 patients (34 %), HBV genotype was determined in 9 out of 13 HDV positive patients, 6 were genotype A and 3 genotype D. Furthermore HCV serology was known in 141 individuals; anti-HCV was identified in 31
patients (22%) and HCV RNA was measurable in nine of these patients (median 2.6 ×10⁶ copies/mL). The majority of HIV/HCV/HBV co-infected patients (23 patients, 74%) were HBV genotype D-infected, while a smaller group (8 patients, 26%) was HBV genotype A-infected (4 A, 2 A + D and 2 A + G). Of the 9 viremic HCV-infected patients, 8 (89%) had HBV genotype D and one patient had HBV genotype A + D.

HBV genotypic resistance testing
In all 143 patients genotypic resistance testing was performed. In three patients, there was insufficient HBV DNA to perform resistance testing. Prior to TDF initiation, 89/143 patients (62%) had wild type virus without mutations and 54/143 patients (38%) had LAM-resistance mutations (Table 3). In follow-up samples from 12 patients who exhibited a delayed response to TDF, genotypic mutations were detected in four, although no resistance associated mutations against TDF were identified (see below).

Efficacy of TDF on HBV suppression
In 131 patients (92%), TDF completely suppressed HBV DNA below the limit of detection (<20 IU/mL) within 6 months, while in 12 patients (8%) suppression of HBV DNA was delayed (Table 4). In the 12 patients with a delayed response to TDF, HBV was detectable between 28 and 132 weeks after TDF initiation. All 12 patients were infected with HBV genotype A (5 [42%] A + G) and previously exposed to LAM. Of the 131 patients 119 (91%) were previously exposed to LAM, thus there is no difference in LAM exposure in the two groups (p = 0.6). In eight of the 12 patients (67%), no genotypic resistance was detected, while in four known genotypic resistances were identified; three patients had pre-existing resistance mutations prior to TDF treatment and one exhibited a changing pattern of resistance over time (Table 4); no resistance mutations to TDF were detected.

One patient, who was treated for many years with LAM, harbored a L180M, M204V mutation six months after initiating TDF treatment (Table 4, Case 1). After 29 months of TDF treatment, HBV-DNA was detectable and the virus changed to a L180M, M204I genotype. Another patient was treated with LAM for 9 years (1995–2004) before it was discontinued due to HIV resistance (Table 4, case 8). In October 2006, the identified virus was wild type (no resistance) and TDF/FTC combination therapy was initiated in November 2006. Six month after initiation, the patient remained viremic and harbored a triple resistance (V173L, L180M, M204V). After a further 8 months of treatment, HBV DNA remained positive and a double mutation (L180M, M204V) was detected.

Discussion
In the Swiss HIV Cohort study, HBV genotype A was predominant in HIV/HBVco-infected participants, followed by genotype D, which is consistent with previous reports [10, 11, 30]. There was no difference in the HBV genotype distribution between different ethnicities, but genotypes differed between HIV transmission risk groups: The majority of HBV genotype A infection was found in MSM whereas IDU was associated with genotype D, which is consistent with data from the EuroSIDA study [11]. Moreover, HBV genotype D infection was predominant in HIV/ HBV/HCV triple infection (73%), and was present in all patients with chronic HCV infection. In contrast to the EuroSIDA study, in the present study, HBV genotyping was performed by direct sequencing of the preS1 gene with subsequent phylogenetic analyses and a commercial hybridization line probe assay was used only in cases where phylogenetic analysis was inconclusive. As the results of the studies are generally in accordance it could be argued that the easier analysis with the commercial hybridization assay is as effective as the time-consuming direct sequencing approach. On the other hand, a greater number of cases of multiple HBV genotype infection were detected in our study, which could be due to the differences in sequencing approaches. In our study, multiple HBV genotype infections were identified in 20 patients (14%), which were all in combination with genotype A (16 A + G and 4 A + D). Mixed infection with different HBV genotypes, subgenotypes and recombinations have been increasingly described especially in highly endemic Asian countries, like China [31] and Thailand [32]. In a recent study from Laos, 5.8% of 446 HBsAg positive blood donors were infected with multiples HBV genotypes [33]. Dual infection (A + D, A + G, and D + G) has also been reported in 8 out of 241 patients (3.3%) from Germany [34] or in a report from Canada [29].

| Table 3 Distribution of resistance mutations prior to TDF treatment in HIV/HBV co-infected patients |
|-----------------------------------------------|
| n HBV genotype | n |
|-----------------|---|
| M204V           | 1 | 1 D |
| L180M + M204V   | 30| 22 A |
|                 |   | 5 A + G |
|                 |   | 1 A + D |
|                 |   | 2 D |
|                 |   | 4 D |
| L180M + M204I   | 7 | 3 D |
|                 |   | 4 D |
| V173L + L180M + M204V | 16| 12 A |
|                 |   | 1 D |
|                 |   | 1 C |
|                 |   | 1 A + G |
|                 |   | 1 A + D |
Treatment with TDF resulted in complete suppression of HBV DNA in 92% of patients within 6 months, and a delayed decline in HBV DNA was observed in 12 patients (8%). No HBV resistance mutation to TDF was found to explain the delayed response, which is consistent with previous studies [16, 35]. Nevertheless, delayed viral suppression or even incomplete HBV-DNA control during prolonged antiviral treatment has been recently described with several reasons for explanation [35, 36] as poor adherence to therapy, altered HBV-specific T cell response in

| Case | HBV genotype | HBV drug | TDF start date | weeks on TDF | HBV viremia (cp/ml) | date analyses | genotypic resistance |
|------|--------------|----------|----------------|--------------|---------------------|---------------|----------------------|
| 1    | A            | exposed to LAM | TDF | 3-Jan-05 | NA | no sample available | 24 | 4630 | 21-Jun-05 | L180M M204V |
|      |              |          |                |              |                     | 101 | NA | 13-Dec-06 | L180M M204V |
|      |              |          |                |              |                     | 132 | NA | 15-Jul-07 | L180M M204I |
| 2    | A + G        | exposed to LAM | TDF | 20-May-04 | 200000 | Before TDF | 125 | 99 | 10-Oct-06 | No resistance |
|      |              |          |                |              | no sample available |     |       |       |                     |
| 3    | A + G        | exposed to LAM | TDF | 18-Apr-05 | 920 | no sample available | 116 | 1520 | 9-Jul-07 | No resistance |
|      |              |          |                |              |                     |     |       |       |                     |
| 4    | A            | exposed to LAM | TDF | 14-Mar-06 | 186'000'000 | no sample available | 39 | 273 | 12-Dec-06 | V173L L180M M204V |
|      |              |          | 28-Jun-06 | TDF + FTC | 100 | No resistance | 73 | 913 | 19-Sep-07 | V173L L180M M204V |
| 5    | A            | exposed to LAM | TDF | 23-Aug-05 | NA | no sample available | 93 | 147 | 6-Jun-07 | No resistance |
|      |              |          |                |              |                     |     |       |       |                     |
| 6    | A + G        | exposed to LAM | TDF | 18-Jan-06 | 10'000'000 | Before TDF | 47 | 240 | 20-Mar-07 | V173L L180M M204I |
|      |              |          |                |              | no sample available |     |       |       |                     |
| 7    | A            | exposed to LAM | TDF | 28-Apr-06 | 793'000'000 | Before TDF | 73 | 913 | 12-Feb-08 | L180M M204V |
|      |              |          |                | TDF + FTC | 28 | No resistance | 25 | 55 | 23-Jul-07 | No resistance |
| 8    | A            | exposed to LAM | TDF | 9-Nov-06 | 11'000'000 | Before TDF | 47 | 240 | 20-Mar-07 | V173L L180M M204V |
|      |              |          |                | TDF + FTC | 28 | No resistance | 73 | 913 | 12-Feb-08 | L180M M204V |
| 9    | A + G        | exposed to LAM | TDF | 25-Sep-06 | 9'000'000 | Before TDF | 43 | 55 | 23-Jul-07 | No resistance |
|      |              |          |                |              | no sample available |     |       |       |                     |
| 10   | A            | exposed to LAM | TDF | 30-Mar-07 | 76'690'000 | Before TDF | 37 | 252 | 17-Dec-07 | No resistance |
|      |              |          |                |              | no sample available |     |       |       |                     |
| 11   | A + G        | exposed to LAM | TDF | 2-Feb-07 | 727'000 | no sample available | 36 | 128'000 | 9-Oct-07 | No resistance |
|      |              |          |                | TDF + FTC | 2-Feb-07 | No resistance | 36 | 128'000 | 9-Oct-07 | No resistance |
| 12   | A            | exposed to LAM | TDF | 5-Feb-07 | 75 | No sample available | 28 | 49 | No sample available | No resistance |
|      |              |          |                |              |                     |     |       |       |                     |
HIV infection [37] and the rt194T polymerase mutation [38]. However, if the viral genotype influences this setting has not yet examined. In our study, all 12 patients were HBV genotype A-infected and five (42%) had a double HBV genotype A + G infection. In addition, all patients had been previously treated with LAM. In a recent study, a delayed response to TDF was observed in 15% of HIV/HBV-co-infected patients who added TDF to LAM. In these patients with a delayed response to TDF no resistance to TDF was detected, which is consistent with the findings of the present study [39]. Moreover, Boyd et al., described again recently that 14% of co-infected HIV/HBV infected patients had detectable viral load even 12 month after start of TDF without identifying specific mutations in the polymerase gene which may explain this delay [35]. Interestingly, in this study HBV genotype is available in many, but not all patients and 63% of patient with transient viremia were genotype A and even more 77% of patients with persistent high or low level viremia [35]. This high numbers of genotype A in "difficult to treat patients" were not further discussed but indicate towards our findings. Furthermore, a chart review of 31 HIV/HBV-coinfected patients reported a shorter time to suppression of HBV DNA in LAM-naive patients treated with TDF and FTC (n = 12) compared with patients in whom LAM had previously failed (n = 19) [40]. The median time to complete suppression of HBV was 466 days in the LAM-naive group compared with 877 days in patients who had previously received LAM (P = 0.001). After 24 months, 5/5 (100%) LAM-naive patients had an undetectable HBV DNA level compared with 4/13 (31%) prior-LAM patients (P = 0.015). However, the influence of HBV genotype on TDF + FTC efficacy was not reported.

Taken together, in our study we found a common virological characteristic, present in all patients that had a delayed antiviral response to TDF. The definition of HBV genotype is a sequence polymorphism difference of more than 8% of the genome [19] and this may play a role in the immunological control [41] that is clearly needed in the antiviral treatment with TDF. Nevertheless, this hypothesis of different immune regulation needs to be confirmed in larger studies and linked to other parameters as pretreatment LAM mutations.

Our study has limitations due to the retrospective nature of the analysis. Notably, it was not possible to compare the status of liver disease (histology or transient elastography) together with the genotype distribution and correlate this with liver disease progression, as these data were not available in the database. However, the high number of coinfected patients and the accuracy of genotype analyses added strength to the study.

Conclusion
In conclusion, these data confirm that the most frequent HBV genotype in HIV/HBV-coinfected patients is genotype A, followed by genotype D, and that the genotype distribution is associated with the risk for HIV acquisition. Our results also suggest that a higher proportion of multiple HBV genotype infections may be present in HIV/HBV-coinfected patients than previously reported. In addition, our results demonstrated complete suppression of HBV DNA in 92% of TDF-treated patients within 6 months, yet a minority of patients (8%) exhibited a delayed virological response to TDF but all without HBV resistance mutations. Know parameters as prior LAM treatment with selected mutations or poor drug adherence, may influence TDF response even if HBV genotypes A infection as found in this cohort could explain this delay and may have clinical impact but warrants further investigation.

Abbreviations
HBV: Hepatitis B virus; HIV: Human Immunodeficiency virus; TDF: Tenofovir disoproxil fumarate; FTC: Emtricitabine; ART: Antiretroviral therapy.

Competing interests
This study was performed within the framework of the Swiss HIV Cohort Study, supported by the Swiss National Science Foundation and by an unrestricted grant from Gilead Sciences SA, Switzerland. The funding agencies had no role in the design of the study, the collection, analysis and interpretation of the data, the decision to submit for publication, nor in the writing of the manuscript. F.Bihl has received consultant fees from BMS, Roche, Gilead and has received travel grants from Janssen. G. Martinetti has no competing interests. G.Wanderl has no competing interests. R.Weber has received travel grants from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dome, Pfizer, Roche, TRB Chemedica and Tibotec. Dr. Weber's institution has received unrestricted educational grants from GlaxoSmithKline, ViV, and Gilead Sciences. B. Ledergerber has received travel grants, grants or honoraria from Bristol-Myers Squibb, Gilead, Pfizer, ViV, Merck Sharp & Dohme and Janssen. A.Calmy has no competing interests. M.Battegay has no competing interests. M.Cavassini has no competing interests. P.Vernazza has no competing interests. P.Caminada has no competing interests. M.Rickenbach has no competing interests. E.Bernasconi has been consultant for BMS, Gilead, ViV Healthcare, Pfizer, MSD, Janssen, Astra Zeneca, and Astellas. Bernasconi also received travel grants from BMS, Gilead, ViV Healthcare, MSD, Janssen, Astra Zeneca, and Astellas.

Authors’ contributions
FB participated in the design of the study, acquisition of data, analysis and interpretation of data and drafted the manuscript. GM and AC carried out the experiments (viral sequencing and sequence alignments). BL carried out the statistical analyses. GW, RW, AC, MB, MC and PD participated in the design of the study and coordination and helped to draft the manuscript. MR carried out the data management and statistics. EB participated in the design of the study, acquisition of data, analysis and interpretation of data and drafted the manuscript. All authors read and approved the final manuscript.

Authors’ information
We are grateful to Antonella Demarta and Renzo Lucchini for the valuable contribution to the laboratory analysis. Medical writing support was provided by NSM Ltd, Moggen, Switzerland. The members of the Swiss HIV Cohort Study are Barth J, Battegay M, Bernasconi E, Böni J, Burcher HC, Burton- Jeangros C, Calmy A, Cavassini M, Cellier C, Egger M, Elzi L, Fehr J, Fellay J, Flépp M, Furrer H (Chairman of the Clinical and Laboratory Committee), Fux CA, Gorjoniëks M, Günthard H (President of the SHCS), Haery D (deputy of "Positive Council"), Haes B, Hirsch HH, Hirschel B, Hödl I, Kahlt I, Kaiser C, Keiser O, Kind C, Klimkait T, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Metzner K, Müller N, Nadal D, Pantaleo G, Rauch A (Chairman of the Scientific Board), Renegass S, Rickenbach M (Head of Data Center), Rudin C (Chairman of the Mother & Child Substudy), Schmid P, Schultze D, Schöni-Affolter F, Schuppliach J, Speck R, Taffel P, Tarr F, Teletti A, Trkola A, Vernazza P, Weber R, Yerly S.
Author details
1Cantonal Hepatobiliary Unit, Ente Ospedaliera Cantonale, Ospedale San Giovanni Bellinzona, Switzerland and Gastroenterology and Hepatology Service, University Hospital of Geneva, Geneva, Switzerland. 2Institute of Microbiology, Ente Ospedaliera Cantonale, Bellinzona, Switzerland. 3Department of Infectious Diseases, University Hospital of Bern, Bern, Switzerland. 4Division of Infectious Diseases and University Hospital of Zurich, Zurich, University of Zurich, Zurich, Switzerland. 5Division of Infectious Diseases, University Hospital of Basel, Basel, Switzerland. 6Division of Infectious Diseases, University Hospital of Lausanne, Lausanne, Switzerland. 7Division of Infectious Diseases, Cantonal Hospital of S. Gallen, St. Gallen, Switzerland. 8SHCS Datacenter, Lausanne, Switzerland. 9Division of Infectious Diseases, Regional Hospital of Lugano, Lugano, Switzerland.

Received: 23 November 2014 Accepted: 24 June 2015
Published online: 08 July 2015

References
1. Keurotis AP, Bultems M, Hu DJ, Jameson DJ. HIV-HBV coinfection—a global challenge. N Engl J Med. 2012;366(19):1749–52.
2. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the DAD study. Arch Intern Med. 2006;166(15):1632–41.
3. Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV-infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005;43(5):795–805.
4. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol. 2005;34(1):121–30.
5. Thio CL, Seaberg EC, Skolasky Jr R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360(9349):1921–2.
6. Ramos B, Nunez M, Martin-Carbonero L, et al. Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus–coinfected patients. J Acquir Immune Defic Syndr. 2007;44(3):290–6.
7. Nunez M, Ramos B, Diaz-Pollan B, et al. Virological outcome of chronic hepatitis B on long-term tenofovir: Virological and clinical implications. AIDS Res Hum Retroviruses. 2003;19(5):557–61.
8. Nunez M, Ramos B, Diaz-Pollan B, et al. Virological outcome of chronic hepatitis B virus infection in HIV–coinfected patients receiving anti-HBV active antiretroviral therapy. AIDS Res Hum Retroviruses. 2006;22(9):842–8.
9. Cooley L, Ayres A, Bartholomeusz A, et al. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV–HBV co-infected individuals. AIDS. 2003;17(11):1649–57.
10. Zehender G, De Maddalena C, Milazzo L, et al. Multilocus typing for hepatitis B virus and hepatitis C virus detection in HIV–co-infected patients. Gastroenterol. 2003;125(5):1559–60. author reply 660.
11. Lacombe K, Massari V, Girard PM, et al. Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. AIDS. 2006;20(3):419–27.
12. Soriano V, Mocroft A, Peters L, et al. Predictors of hepatitis B virus genotype and viremia in HIV-infected patients with chronic hepatitis B in Europe. J Antimicrob Chemother. 2010;65(5):548–55.
13. Martin-Carbonero L, Teixeira T, Poveda E, et al. Clinical and virological outcomes in HIV–infected patients with chronic hepatitis B on long-term nuclootide analogues. AIDS. 2011;25(1):173–9.
14. Matthews GV, Seaberg EC, Dore GJ, et al. Combination HBV therapy is linked to greater HIV DNA suppression in a cohort of lamivudine-experienced HIV–HBV–coinfected individuals. AIDS. 2009;23(13):1707–15.
15. Lacombe K, Gozlan J, Boelle PY, et al. Long-term hepatitis B virus dynamics in HIV–hepatitis B virus co-infected patients treated with tenofovir disoproxil fumarate. AIDS. 2005;19(9):907–15.
16. Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B virus infection in HIV-infected adults. HIV Med. 2009;10(2):82–8.
17. Kritinos KM, Corsa A, Liu Y, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014;59(2):343–42.
18. Ratcliffe L, Beadsworth MB, Pennell A, Phillips M, Vlar FJ. Managing hepatitis B V co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients. AIDS. 2011;25(1):91–6.